Corazon (Corsee) D. Sanders
CIK 1796536 · last filed 2026-10-01
Corazon (Corsee) D. Sanders is a corporate insider who has filed 48 SEC Form 4 insider transactions across 6 companies since 2019. The most recent filing shows the insider sold $258.9K of LEGN on Oct 1, 2026. Across all open-market trades the lifetime net is −$2.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions. 18 SEC filings were submitted jointly with Ultragenyx Pharmaceutical Inc. 18 Form 144 notices of planned sales are also on file; the latest, for Legend Biotech Corp on Sep 29, 2026, lists the filer as a director. 5 sales listed on those notices, worth $1.2M in all, have no matching Form 4.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ONC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
9301 AMBERGLEN BLVD, SUITE 100
AUSTIN, VI 78729
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LEGN | Director | 52,731 | $16.14 | $851.1K | -$258.9K | 2 | 2026-10-01 |
| CLDI | Director | — | $0.50 | — | $0 | 1 | 2026-08-19 |
| RARE | Director | 21,095 | $17.16 | $362.0K | -$339.4K | 11 | 2026-06-15 |
| ONC | Director | 0 | $399.06 | $0 | -$1.86M | 4 | 2026-05-27 |
| Molecular Templates, Inc. (MTEM) Delisted | Director | — | $0.00 | — | $0 | 6 | 2024-09-30 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 46,241 | $184.71 | $8.54M | -$105.4K | 6 | 2024-06-07 |
Recent Filings
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-01 | LEGN | Sell (S) | −27,370 | -$258.9K | EDGAR |
| 2026-09-29 | Legend Biotech Corp | Notice (144) Director · Planned Sep 29, 2026 No sale on file |
−13,685 | -$258.9K | EDGAR |
| 2026-09-28 | LEGN | Grant (A) | +20,986 | $0 | EDGAR |
| 2026-08-25 | BeOne Medicines Ltd. | Notice (144) Former Director · Planned Aug 25, 2026 No sale on file |
−2,075 | -$788.5K | EDGAR |
| 2026-08-19 | CLDI | Grant (A) | — | $0 | EDGAR |
| 2026-06-15 | BeOne Medicines Ltd. | Notice (144) Director · Planned Jun 15, 2026 Sold: listed on the Aug 25, 2026 notice |
−945 | -$250.9K | EDGAR |
| 2026-06-15 | RARE | Notice (144) Director · Planned Jun 15, 2026 Sold: Form 4 filed Jun 15, 2026 |
−2,000 | -$50.1K | EDGAR |
| 2026-06-15 | RARE | Sell (S) | −2,000 | -$50.1K | EDGAR |
| 2026-05-27 | ONC | Sell (S) | −212 | -$65.6K | EDGAR |
| 2026-05-22 | BeOne Medicines Ltd. | Notice (144) Director · Planned May 22, 2026 Sold: listed on the Jun 15, 2026 notice |
−212 | -$65.6K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).
Sales Reported Only on Form 144
5 sales · $1.24M| Sold | Symbol | Shares | Proceeds | Avg Price | Listed On |
|---|---|---|---|---|---|
| 2026-06-15 | BeOne Medicines Ltd. | 945 | $250.9K | $265.50 | 2026-08-25 |
| 2026-05-22 | BeOne Medicines Ltd. | 212 | $65.6K | $309.59 | 2026-06-15 |
| 2025-09-05 | BeOne Medicines Ltd. | 2,665 | $898.1K | $337.00 | 2025-11-26 |
| 2025-06-24 | Legend Biotech Corp | 307 | $10.6K | $34.37 | 2025-09-23 |
| 2025-03-25 | Legend Biotech Corp | 307 | $11.2K | $36.33 | 2025-06-24 |